Prior studies that align with our results had shown that MIP-1α/CCL3 and RANTES/CCL5 increased in AIA and CIA models, suggesting that these chemokines could be therapeutic targets in RA (Szekanecz et al. 2000; Thornton et al. 1999). The gene discussed is CCL3; the disease is rheumatoid arthritis.